PetMed Express, Inc. (PETS) Earnings Call Transcripts
PetMed Express, Inc.'s Latest Earnings Call - Q4 FY2026
In the fiscal fourth quarter of 2026, PetMed Express reported net sales of $42.8 million, a decline of 15.6% year-over-year, but showed sequential improvement from Q3, signaling potential stabilization in its core business. The company incurred a net loss of $4.1 million, significantly reduced from a loss of $11.6 million in the prior year quarter. Management highlighted operational improvements and cost reduction efforts, while also indicating that the strategic initiatives implemented in the second half of the year are beginning to yield positive results, setting a foundation for future growth.
Reported metrics
| Metric | Value |
|---|---|
| Q4 Net Sales | $42.8 million (miss) |
| Full Year Net Sales | $179 million (miss) |
| Q4 Gross Profit | $13.9 million (miss) |
| Q4 Net Loss | $4.1 million (beat) |
| Full Year Net Loss | $57.3 million (miss) |
| Q4 Adjusted EBITDA | $-2.8 million (miss) |
Guidance from management
Management expressed confidence in building on the improvements made during fiscal year 2026, focusing on operational excellence and customer retention. No specific financial guidance was provided for fiscal year 2027.
What analysts pressed on
Analysts expressed concerns regarding the ongoing decline in prescription medication sales, which significantly impacted revenue. Additionally, there were questions about the sustainability of the recent operational improvements and whether the company can maintain its momentum into fiscal year 2027.
Main topics on the call
- Sequential Sales Improvement — PetMed Express experienced a sequential increase in net sales in Q4, marking its first quarterly increase since fiscal year 2024. Management noted, "we saw a modest sequential improvement from Q3, driven by improvements ...
- Cost Reduction Initiatives — The company implemented significant cost reduction measures, leading to an 8.6% decrease in general and administrative expenses in Q4. Management stated, "we also made meaningful progress on cost reduction efforts includ...
- Regulatory Compliance and Internal Controls — PetMed regained regulatory compliance with the filing of its Form 10-K for fiscal year 2025 and remediated three previously disclosed material weaknesses. Management emphasized this as a critical step for operational sta...
- Nonrecurring Charges Impacting Loss — The reported net loss for fiscal year 2026 included several significant nonrecurring charges, such as a $26.7 million goodwill impairment and $4.5 million in legal and severance costs. This contributed to a net loss of $...
Read the full PetMed Express, Inc. transcript (Q4 FY2026) → Summary generated from the call transcript; every figure above is stated by management on the record.
About PetMed Express, Inc.
PetMed Express, Inc. (PETS) is a publicly listed company in the Specialty Retail industry, within the Consumer Discretionary sector. It trades on NasdaqGS and is based in US. EarningsCalls.dev maintains a free, full-text archive of its earnings call transcripts — 52 calls on record spanning January 21, 2020 to June 2, 2026. Every transcript is split into speaker-by-speaker segments with headline metrics, free to read or available through our REST API.
Earnings Call History
EarningsCalls.dev has 52 PetMed Express, Inc. earnings call transcripts on record, spanning January 21, 2020 to June 2, 2026. Based on this history, PetMed Express, Inc. reports quarterly. The most recent call on file is dated June 2, 2026. The full list is below — each row opens the complete, free-to-read transcript.
- Ticker
- PETS
- Exchange
- NasdaqGS
- Country
- US
- Sector
- Consumer Discretionary
- Industry
- Specialty Retail
- Calls on record
- 52
- First call
- January 21, 2020
- Most recent
- June 2, 2026
- Reporting cadence
- quarterly